Naglazyme (Galsulfase)

Galsulfase, the active ingredient in Naglazyme, is an enzyme replacement therapy presented as an injectable solution for intravenous use. It is approved in the European Union for the treatment of mucopolysaccharidosis type VI (Maroteaux‑Lamy syndrome), a rare lysosomal storage disorder, by replacing the deficient N‑acetylgalactosamine‑4‑sulfatase enzyme in patients.

GNH USA supplies Naglazyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on reliable cold‑chain logistics and regulatory compliance.

Naglazyme is used in enzyme replacement therapy for the lysosomal storage disorder mucopolysaccharidosis type VI.

Mucopolysaccharidosis type VI (Maroteaux‑Lamy syndrome): Improves degradation of accumulated glycosaminoglycans, helping to stabilize or slow disease progression.

Adverse reactions reported with Naglazyme may vary in frequency and severity.

Common Side Effects: - Infusion‑related reactions such as fever, chills, and headache - Nausea or vomiting during or shortly after infusion - Mild abdominal discomfort - Transient elevation of liver enzymes - Fatigue or malaise - Injection site erythema

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions - Significant hepatic dysfunction (elevated transaminases, jaundice) - Thrombocytopenia or other hematologic abnormalities - Pulmonary hypertension - Severe infusion‑related cardiovascular events - Development of neutralizing antibodies affecting efficacy

When using Naglazyme, several precautionary measures should be observed to ensure patient safety.

Infusion monitoring: Observe patients during and after administration for signs of reaction. Renal function: Assess baseline kidney status and monitor periodically. Hepatic function: Check liver enzymes before initiation and during therapy. Immunogenicity: Be aware of possible antibody formation that may alter efficacy. Pregnancy and lactation: Use only if the potential benefit justifies the potential risk, as safety data are limited. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Naglazyme may interact with other medicines; awareness of potential interactions helps manage risk.

Major Interactions (Avoid): - Concomitant administration of other lysosomal enzyme replacement products targeting the same pathway. - Live attenuated vaccines: may reduce vaccine efficacy or increase infection risk.

Moderate Interactions (Monitor Closely): - Immunosuppressive agents: may increase susceptibility to infections. - Anticoagulants: monitor coagulation parameters if platelet changes occur during infusion. - Antipyretics or analgesics: may mask early signs of infusion reactions; use with caution.